Disc Medicine Announces Presentation of Initial Data from – GlobeNewswire

Report on Disc Medicine’s Contribution to Global Health Goals through Hematologic Disease Research

Advancing SDG 3: Good Health and Well-being

Disc Medicine, Inc., a clinical-stage biopharmaceutical company, is actively contributing to the United Nations Sustainable Development Goal 3 (SDG 3) by developing novel treatments for serious hematologic diseases. The company’s focus on addressing unmet medical needs aligns directly with Target 3.4, which aims to reduce premature mortality from non-communicable diseases. By advancing its clinical programs, Disc Medicine seeks to improve the quality of life and health outcomes for patients globally.

Fostering Innovation and Scientific Collaboration (SDG 9 & SDG 17)

In line with SDG 9 (Industry, Innovation, and Infrastructure) and SDG 17 (Partnerships for the Goals), Disc Medicine will disseminate key clinical findings at the upcoming American Society of Hematology (ASH) Annual Meeting in Orlando, FL, from December 6-9, 2025. This participation underscores the company’s commitment to scientific innovation and collaborative knowledge-sharing within the global health community. The presentations will feature initial data from two key clinical trials, representing significant progress in the development of potentially first-in-class therapeutic candidates.

Key Clinical Program Updates at ASH Annual Meeting

The company will present data from two ongoing clinical trials. A management-led conference call is scheduled for Sunday, December 7, at 7:30 am EST to discuss the data and future development strategies.

1. DISC-0974 for Anemia in Myelofibrosis (MF)
   • This presentation will feature initial data from the RALLY-MF Phase 2 trial.
   • The trial evaluates DISC-0974 as both a monotherapy and in combination with JAK inhibitor therapies.
   • This research addresses a critical health issue for patients with myelofibrosis, contributing to the broader goal of ensuring healthy lives.
2. DISC-3405 for Polycythemia Vera (PV)
   • This presentation will detail the design of the ongoing Phase 2 trial for DISC-3405.
   • Initial data readouts for this trial and a Phase 1b trial in sickle cell disease are anticipated in 2026.
   • This program represents another innovative approach to managing serious hematologic diseases.

Scheduled Poster Presentation Details

The following presentations are scheduled for Saturday, December 6, from 5:30 pm to 7:30 pm EST.

• DISC-0974 Presentation

  • Publication Number: 2042
  • Title: RALLY MF: A phase 2 Study of DISC-0974, an anti-hemojuvelin antibody, in patients with myelofibrosis and anemia
  • Presenting Author: Naseema Gangat, M.B.B.S.

• DISC-3405 Presentation

  • Publication Number: 2053
  • Title: A phase 2, open-label study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of DISC-3405 in participants with polycythemia vera (PV)
  • Presenting Author: Marcus Carden, M.D., M.Sc.

Analysis of Sustainable Development Goals in the Article

1. Which SDGs are addressed or connected to the issues highlighted in the article?

1. SDG 3: Good Health and Well-being

   • The article is entirely focused on the development of new medical treatments for “patients suffering from serious hematologic diseases.” This directly aligns with the goal of ensuring healthy lives and promoting well-being for all at all ages. The company, Disc Medicine, is working on treatments for specific conditions like anemia of myelofibrosis (MF), polycythemia vera, and sickle cell disease, which contributes to improving health outcomes for affected individuals.

2. SDG 9: Industry, Innovation, and Infrastructure

   • The article highlights the work of a “clinical-stage biopharmaceutical company” engaged in the “discovery, development, and commercialization of novel treatments.” This represents scientific research and technological innovation within the pharmaceutical industry. The company’s efforts to create “potentially first-in-class therapeutic candidates” by targeting “fundamental biological pathways” is a clear example of the innovation called for in SDG 9.

2. What specific targets under those SDGs can be identified based on the article’s content?

1. Target 3.4: Reduce premature mortality from non-communicable diseases

   • The diseases mentioned in the article—myelofibrosis, polycythemia vera, and sickle cell disease—are serious, non-communicable hematologic diseases. By developing “novel treatments” for these conditions, Disc Medicine is directly contributing to the effort to reduce illness and premature death caused by such diseases.

2. Target 3.b: Support the research and development of vaccines and medicines

   • The article is a announcement about the progress of clinical trials (“RALLY-MF Phase 2 trial of DISC-0974” and “Phase 2 trial of DISC-3405”). This is a direct manifestation of research and development (R&D) for new medicines aimed at treating non-communicable diseases, which is the core focus of this target.

3. Target 9.5: Enhance scientific research and encourage innovation

   • The article describes a company “committed to discovering, developing, and commercializing novel treatments.” The entire press release details the company’s R&D activities, including presenting initial data from a “Phase 2 trial” and the design of another. This embodies the private sector’s role in enhancing scientific research and fostering innovation within a key industrial sector.

3. Are there any indicators mentioned or implied in the article that can be used to measure progress towards the identified targets?

1. Implied Indicator: Progress in clinical trials for new treatments

   • The article does not cite official SDG indicators but provides clear, implicit measures of progress. The announcement of “initial data from the RALLY-MF Phase 2 trial” and updates on the “Phase 1b trial of DISC-3405” serve as concrete indicators of ongoing R&D and progress towards developing new medicines. The different phases of clinical trials (Phase 1, 2, etc.) are standard industry metrics for tracking the development of new therapies.

2. Implied Indicator: Development of novel therapeutic candidates

   • The article mentions specific drug candidates, “DISC-0974” and “DISC-3405,” which are described as “potentially first-in-class therapeutic candidates.” The existence and advancement of these candidates through the clinical trial pipeline is a direct indicator of innovation and scientific research aimed at addressing unmet medical needs in serious diseases.

4. SDGs, Targets and Indicators Table

Source: globenewswire.com